PARP1 and cancer: proposed that SLFN11 enhances the activity of PARP inhibitors by inhibiting DNA replication (7), while others suggested that SLFN11 creates a “BRCAness” state by inhibiting homologous recombination repair (RPA-dependent mechanism), making cancer cells sensitive to PARP inhibitors (8, 32).